FDA inspection
Shandong Lixin Pharmaceutical Co., Ltd.: FDA inspection ending May 19, 2023
FDA inspection 1209019 · No Action Indicated (NAI) · Zibo
Key facts
| Inspection ID | 1209019 |
|---|---|
| Firm | Shandong Lixin Pharmaceutical Co., Ltd. |
| FEI number | 3017297099 |
| Address | Gaoqing County, No. 9 Jinyang Road; Economic Development Zone |
| City | Zibo |
| Fiscal year | 2023 |
| Inspection end date | May 19, 2023 |
| Classification | No Action Indicated (NAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data